Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more
Well-informed patients often experience better treatment outcomes
Abbreviations MASLD : Metabolic dysfunction-associated steatotic liver disease MASH : Metabolic dysfunction-associated steatohepatitis T2DM : Type 2 diabetes mellitus GLP-1 RAs : Glucagon-like peptide-1 receptor agonists GIP : Glucose-dependent insulinotropic polypeptide GCG : Glucagon AACE : American Association of Clinical Endocrinology AASLD : American Association for the Study of the Liver Diseases F2 : Fibrosis grade 2 ABCD : Adiposity-based chronic diseases EASO : European Association for the Study of Obesity VAT : Visceral adipose tissue FFA : Free fatty acids HSC : Hepatic stellate cells FDA : Food and drug administration F3 : Fibrosis grade 3 AST : Aspartate aminotransferase ALT : Alanine aminotransferase GGT : Gamma-glutamyl transferase NAFLD : Non-alcoholic fatty liver-disease LFC : Liver fat content MRI-PDFF : Magnetic resonance imaging derived proton density fat fraction ELF : Enhanced liver fibrosis FIB-4 : Fibrosis-4 index F1 : Fibrosis grade 1 NAS : NAFLD activity score AE : Adverse event SAE : Serious adverse event EMA : European Medicine Agency FGF21 : Fibroblast growth factor 21 MetALD : Metabolic dysfunction and alcohol-related liver disease References Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, Cheung R, Nguyen MH
The clinical-scale manufacturing segment is projected to grow at a CAGR of 15.6%, supported by increasing R&D activities involving next-generation GLP-1, dual GIP/GLP-1, and multi-receptor peptide therapeutics
Malagelada C, Zong HJ, Greene LA
